The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has accelerated approval as a second-line treatment for HER2-mutated NSCLC and is dosed ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...

Ingelheim: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

The FDA has granted Priority Review to Boehringer Ingelheim's new drug application for its non-small cell lung cancer therapy ...

The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...